Alpha Teknova, Inc. (TKNO) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Alpha Teknova, Inc. (TKNO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Alpha Teknova, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • No newly added risk factors disclosed compared to prior 10-K
- • Operating loss reduced to $4.3M Q3 2025 from $7.6M Q3 2024 reflecting modest expense increase but ongoing unprofitability risk
- • Potential stock price decline from immediate resale of 53.5M outstanding shares held mostly by affiliates with Rule 144 sale restrictions
- • Market perception of large restricted share sales could impair future capital raise efforts impacting near-term liquidity
- • Share dilution risk from 12.5M stock options and 1.2M ESPP shares reserved for issuance, plus future automatic increases in 2025
Alpha Teknova, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$10M
▲ +9.2% YoY▲ +1.6% QoQ
Net Income
-$4M
▲ +43.3% YoY▼ -20.1% QoQ
Gross Margin
30.7%
▲ +2973bp YoY▼ -806bp QoQ
Operating Margin
-38.4%
▲ +3919bp YoY▼ -551bp QoQ
Net Margin
-41.0%
▲ +3800bp YoY▼ -629bp QoQ
ROE
-5.9%
Total Assets
$108M
EPS (Diluted)
$-0.08
▲ +42.9% YoY▼ -33.3% QoQ
Operating Cash Flow
-$2M
▲ +3.8% YoY▲ +5.8% QoQ
Source: XBRL data from Alpha Teknova, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alpha Teknova, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.